Your browser doesn't support javascript.
loading
Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.
Lidsky, Michael E; Wang, Zechen; Lu, Min; Liu, Annie; Hsu, S David; McCall, Shannon J; Sheng, Zhecheng; Granek, Joshua A; Owzar, Kouros; Anderson, Karen S; Wood, Kris C.
Afiliação
  • Lidsky ME; Department of Surgery, Duke University School of Medicine, Durham, NC, USA. michael.lidsky@duke.edu.
  • Wang Z; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.
  • Lu M; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
  • Liu A; Department of Surgery, Duke University School of Medicine, Durham, NC, USA.
  • Hsu SD; Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • McCall SJ; Department of Pathology, Duke University School of Medicine, Durham, NC, USA.
  • Sheng Z; Department of Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
  • Granek JA; Department of Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
  • Owzar K; Department of Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
  • Anderson KS; Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.
  • Wood KC; Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT, USA.
NPJ Precis Oncol ; 6(1): 75, 2022 Oct 23.
Article em En | MEDLINE | ID: mdl-36274097

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article